Korean J Physiol Pharmacol.  2022 Nov;26(6):405-413. 10.4196/kjpp.2022.26.6.405.

The physiological and pharmacological roles of prostaglandins in hair growth

• Shin DW

• KMID: 2534517
• DOI: http://doi.org/10.4196/kjpp.2022.26.6.405

Abstract

Hair loss is a common status found among people of all ages. Since the role of hair is much more related to culture and individual identity, hair loss can have a great influence on well-being and quality of life. It is a disorder that is observed in only scalp patients with androgenetic alopecia (AGA) or alopecia areata caused by stress or immune response abnormalities. Food and Drug Administration (FDA)-approved therapeutic medicines such as finasteride, and minoxidil improve hair loss temporarily, but when they stop, they have a limitation in that hair loss occurs again. As an alternative strategy for improving hair growth, many studies reported that there is a relationship between the expression levels of prostaglandins (PGs) and hair growth. Four major PGs such as prostaglandin D2 (PGD₂ ), prostaglandin I2 (PGI₂ ), prostaglandin E2 (PGE₂ ), and prostaglandin F2 alpha (PGF_2α ) are spatiotemporally expressed in hair follicles and are implicated in hair loss. This review investigated the physiological roles and pharmacological interventions of the PGs in the pathogenesis of hair loss and provided these novel insights for clinical therapeutics for patients suffering from alopecia.

Keyword

Alopecia areata; Androgenetic alopecia; Cyclooxygenase; Hair follicle; Prostaglandin

Figure

• 

  Fig. 1 Diagram of prostanoids and their biological effects on hair follicles through stimulating different type of G protein-coupled receptors. Prostanoids are classified into five types, namely thromboxane A2 (TXA2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), and prostaglandin I2 (PGI2). PGD2 binds to prostaglandin D2 receptors (DP1, DP2), whereas PGE2 binds to prostaglandin E2 receptors (EP1, EP2, EP3, EP4). PGF2α binds to the prostaglandin F2α receptor (FP). PGI2 binds to the prostaglandin I2 receptor (IP). TXA2 binds to the thromboxane A2 receptor (TP). Human hair follicles remarkably expressed microsomal PGES (mPGES)-1, mPGES-2, and cytosolic PGES (cPGES), which converts PGH2 to PGE2. These human hair follicles also significantly expressed AKR1C3/PGFS, which catalyzes PGH2 to PGF2α. In addition, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), prostaglandin G2 (PGG2), prostaglandin H2 (PGH2), PGD2 synthase (PGDS), PGE2 synthase (PGES), PGF2α synthase (PGFS), PGI2 synthase (PGIS) are marked.

Reference

1. Botchkarev VA, Kishimoto J. 2003; Molecular control of epithelial-mesenchymal interactions during hair follicle cycling. J Investig Dermatol Symp Proc. 8:46–55. DOI: 10.1046/j.1523-1747.2003.12171.x. PMID: 12894994. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0041868117&origin=inward.

2. Stenn KS, Paus R. 2001; Controls of hair follicle cycling. Physiol Rev. 81:449–494. DOI: 10.1152/physrev.2001.81.1.449. PMID: 11152763. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035134022&origin=inward.

3. Kaufman KD. 2002; Androgens and alopecia. Mol Cell Endocrinol. 198:89–95. DOI: 10.1016/S0303-7207(02)00372-6. PMID: 12573818. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0037203503&origin=inward.

4. Sawaya ME, Keane RW, Blume-Peytavi U, Mullins DL, Nusbaum BP, Whiting D, Nicholson DW. 2001; Androgen responsive genes as they affect hair growth. Eur J Dermatol. 11:304–308. PMID: 11399535. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0034936539&origin=inward.

5. Bak DH, Choi MJ, Kim SR, Lee BC, Kim JM, Jeon ES, Oh W, Lim ES, Park BC, Kim MJ, Na J, Kim BJ. 2018; Human umbilical cord blood mesenchymal stem cells engineered to overexpress growth factors accelerate outcomes in hair growth. Korean J Physiol Pharmacol. 22:555–566. DOI: 10.4196/kjpp.2018.22.5.555. PMID: 30181702. PMCID: PMC6115345. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052861159&origin=inward.

6. Inui S, Itami S. 2013; Androgen actions on the human hair follicle: perspectives. Exp Dermatol. 22:168–171. DOI: 10.1111/exd.12024. PMID: 23016593. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875050350&origin=inward.

7. Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. 2018; A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 17:457–463. PMID: 29601622. PMCID: PMC6609098. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053729398&origin=inward.

8. Jimenez F, Alam M, Vogel JE, Avram M. 2021; Hair transplantation: basic overview. J Am Acad Dermatol. 85:803–814. DOI: 10.1016/j.jaad.2021.03.124. PMID: 33905785. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85114433698&origin=inward.

9. Adil A, Godwin M. 2017; The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 77:136–141.e5. DOI: 10.1016/j.jaad.2017.02.054. PMID: 28396101. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85017108673&origin=inward.

10. Sasaki S, Hozumi Y, Kondo S. 2005; Influence of prostaglandin F₂α and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 14:323–328. DOI: 10.1111/j.0906-6705.2005.00270.x. PMID: 15854125. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=18844450968&origin=inward.

11. Nieves A, Garza LA. 2014; Does prostaglandin D₂ hold the cure to male pattern baldness? Exp Dermatol. 23:224–227. DOI: 10.1111/exd.12348. PMID: 24521203. PMCID: PMC3982925. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84896995060&origin=inward.

12. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. 2009; Prostanoids in health and disease. J Lipid Res. 50(Suppl):S423–S428. DOI: 10.1194/jlr.R800094-JLR200. PMID: 19095631. PMCID: PMC2674745. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=66349102248&origin=inward.

13. Colombe L, Vindrios A, Michelet JF, Bernard BA. 2007; Prostaglandin metabolism in human hair follicle. Exp Dermatol. 16:762–769. DOI: 10.1111/j.1600-0625.2007.00586.x. PMID: 17697149. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34547912906&origin=inward.

14. Guevara-Balcazar G, Ramirez-Sanchez I, Mera-Jimenez E, Rubio-Gayosso I, Aguilar-Najera ME, Castillo-Hernandez MC. 2017; Participation of COX-1 and COX-2 in the contractile effect of phenylephrine in prepubescent and old rats. Korean J Physiol Pharmacol. 21:407–413. DOI: 10.4196/kjpp.2017.21.4.407. PMID: 28706454. PMCID: PMC5507779. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85023747329&origin=inward.

15. Colombe L, Michelet JF, Bernard BA. 2008; Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 17:63–72. DOI: 10.1111/j.1600-0625.2007.00639.x. PMID: 18005048. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=37249028593&origin=inward.

16. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G. 2012; Prostaglandin D₂ inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 4:126ra34. DOI: 10.1126/scitranslmed.3003122. PMID: 22440736. PMCID: PMC3319975. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863344412&origin=inward.

17. Xu XG, Chen HD. 2018; Prostanoids and hair follicles: implications for therapy of hair disorders. Acta Derm Venereol. 98:318–323. DOI: 10.2340/00015555-2843. PMID: 29136266. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85043334752&origin=inward.

18. Neufang G, Furstenberger G, Heidt M, Marks F, Müller-Decker K. 2001; Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A. 98:7629–7634. DOI: 10.1073/pnas.121574098. PMID: 11381142. PMCID: PMC34719. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035912711&origin=inward.

19. Bol DK, Rowley RB, Ho CP, Pilz B, Dell J, Swerdel M, Kiguchi K, Muga S, Klein R, Fischer SM. 2002; Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. 62:2516–2521. PMID: 11980643. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0036569925&origin=inward.

20. Müller-Decker K, Leder C, Neumann M, Neufang G, Bayerl C, Schweizer J, Marks F, Fürstenberger G. 2003; Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression. J Invest Dermatol. 121:661–668. DOI: 10.1046/j.1523-1747.2003.12473.x. PMID: 14632179. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0141887557&origin=inward.

21. Kobayashi T, Narumiya S. 2002; Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 68-69:557–573. DOI: 10.1016/S0090-6980(02)00055-2. PMID: 12432943. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0036669383&origin=inward.

22. Kabashima K, Miyachi Y. 2004; Prostanoids in the cutaneous immune response. J Dermatol Sci. 34:177–184. DOI: 10.1016/j.jdermsci.2003.11.008. PMID: 15113587. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=2142810073&origin=inward.

23. Nesher R, Mimouni M, Elnaddaf H, Nemet A, Kidron D. 2015; Characterization of prostaglandin F₂α receptors in human eyelids. Eur J Ophthalmol. 25:81–84. DOI: 10.5301/ejo.5000519. PMID: 25363851. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922694988&origin=inward.

24. Woodward DF, Jones RL, Narumiya S. 2011; International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 63:471–538. DOI: 10.1124/pr.110.003517. PMID: 21752876. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955575162&origin=inward.

25. Gallant MA, Samadfam R, Hackett JA, Antoniou J, Parent JL, de Brum-Fernandes AJ. 2005; Production of prostaglandin D₂ by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J Bone Miner Res. 20:672–681. DOI: 10.1359/JBMR.041211. PMID: 15765187. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=15344348453&origin=inward.

26. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K. 2001; Prostaglandin D₂ selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 193:255–261. DOI: 10.1084/jem.193.2.255. PMID: 11208866. PMCID: PMC2193345. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035862329&origin=inward.

27. Bhargava S. 2014; Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer. Med Hypotheses. 82:428–432. DOI: 10.1016/j.mehy.2014.01.016. PMID: 24548754. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84896733327&origin=inward.

28. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. 2003; Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol. 192:294–306. DOI: 10.1016/S0041-008X(03)00301-6. PMID: 14575647. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0142219780&origin=inward.

29. Nelson AM, Loy DE, Lawson JA, Katseff AS, Fitzgerald GA, Garza LA. 2013; Prostaglandin D₂ inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44. J Invest Dermatol. 133:881–889. DOI: 10.1038/jid.2012.398. PMID: 23190891. PMCID: PMC3593761. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875211689&origin=inward.

30. Joo HW, Kang YR, Kwack MH, Sung YK. 2016; 15-deoxy prostaglandin J₂, the nonenzymatic metabolite of prostaglandin D₂, induces apoptosis in keratinocytes of human hair follicles: a possible explanation for prostaglandin D₂-mediated inhibition of hair growth. Naunyn Schmiedebergs Arch Pharmacol. 389:809–813. DOI: 10.1007/s00210-016-1257-z. PMID: 27185495. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84968583555&origin=inward.

31. Mantel A, McDonald JT, Goldsborough K, Harvey VM, Chan J. 2017; Prostaglandin D₂ uses components of ROS signaling to enhance testosterone production in keratinocytes. J Investig Dermatol Symp Proc. 18:S81–S84. DOI: 10.1016/j.jisp.2017.01.003. PMID: 28941500. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85031732444&origin=inward.

32. Garza LA, Yang CC, Zhao T, Blatt HB, Lee M, He H, Stanton DC, Carrasco L, Spiegel JH, Tobias JW, Cotsarelis G. 2011; Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest. 121:613–622. DOI: 10.1172/JCI44478. PMID: 21206086. PMCID: PMC3026732. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79551525437&origin=inward.

33. Purba TS, Peake M, Farjo B, Farjo N, Bhogal RK, Jenkins G, Paus R. 2017; Divergent proliferation patterns of distinct human hair follicle epithelial progenitor niches in situ and their differential responsiveness to prostaglandin D₂. Sci Rep. 7:15197. DOI: 10.1038/s41598-017-15038-9. PMID: 29123134. PMCID: PMC5680340. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85033705034&origin=inward.

34. Jeong KH, Jung JH, Kim JE, Kang H. 2018; Prostaglandin D₂-mediated DP₂ and AKT signal regulate the activation of androgen receptors in human dermal papilla cells. Int J Mol Sci. 19:556. DOI: 10.3390/ijms19020556. PMID: 29439547. PMCID: PMC5855778. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042232574&origin=inward.

35. Chovarda E, Sotiriou E, Lazaridou E, Vakirlis E, Ioannides D. 2021; The role of prostaglandins in androgenetic alopecia. Int J Dermatol. 60:730–735. DOI: 10.1111/ijd.15378. PMID: 33528035. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85100287770&origin=inward.

36. Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, Sorriso-Valvo L, Di Nunno D, Carlesimo M. 2018; A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat. 29:149–151. DOI: 10.1080/09546634.2017.1341610. PMID: 28604133. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021690991&origin=inward.

37. Zaky MS, Abo Khodeir H, Ahmed HA, Elsaie ML. 2021; Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: a case-controlled study. J Cosmet Dermatol. 20:1154–1159. DOI: 10.1111/jocd.13940. PMID: 33417284. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099361938&origin=inward.

38. Hossein Mostafa D, Samadi A, Niknam S, Nasrollahi SA, Guishard A, Firooz A. 2021; Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: a randomized, single-blind controlled study. J Pharm Pharm Sci. 24:191–199. DOI: 10.18433/jpps31456. PMID: 33909554. PMID: 17c0c79757a443aabf18ae1209269e9c. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105066571&origin=inward.

39. DuBois J, Bruce S, Stewart D, Kempers S, Harutunian C, Boodhoo T, Weitzenfeld A, Chang-Lin JE. 2021; Setipiprant for androgenetic alopecia in males: results from a randomized, double-blind, placebo-controlled phase 2a trial. Clin Cosmet Investig Dermatol. 14:1507–1517. DOI: 10.2147/CCID.S319676. PMID: 34703265. PMCID: PMC8526366. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85120577218&origin=inward.

40. Wen S, Wei J, Bao J, Guo T, Zheng W, Zhuang X, Lin Y. 2020; Effect of levocetirizine hydrochloride on the growth of human dermal papilla cells: a preliminary study. Ann Palliat Med. 9:308–317. DOI: 10.21037/apm.2020.01.15. PMID: 32156129. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85082959422&origin=inward.

41. Johnstone MA. 1997; Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 124:544–547. DOI: 10.1016/S0002-9394(14)70870-0. PMID: 9323945. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0030867340&origin=inward.

42. Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. 2010; Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 24:481–485. DOI: 10.1111/j.1468-3083.2009.03543.x. PMID: 20028444. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77749302366&origin=inward.

43. Faghihi G, Andalib F, Asilian A. 2009; The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol. 19:586–587. DOI: 10.1684/ejd.2009.0766. PMID: 19620039. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=73249131977&origin=inward.

44. Ross EK, Bolduc C, Lui H, Shapiro J. 2005; Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata. J Am Acad Dermatol. 53:1095–1096. DOI: 10.1016/j.jaad.2005.06.031. PMID: 16310083. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=27944434900&origin=inward.

45. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. 2012; A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 66:794–800. DOI: 10.1016/j.jaad.2011.05.026. PMID: 21875758. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84859849330&origin=inward.

46. Rafati M, Mahmoudian R, Golpour M, Kazeminejad A, Saeedi M, Nekoukar Z. 2022; The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial. Dermatol Ther. 35:e15450. DOI: 10.1111/dth.15450. PMID: 35289043. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85126863575&origin=inward.

47. Yoelin S, Walt JG, Earl M. 2010; Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg. 36:638–649. DOI: 10.1111/j.1524-4725.2010.01519.x. PMID: 20384751. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951274423&origin=inward.

48. Wester ST, Lee WW, Shi W. 2010; Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology. 117:1024–1031. DOI: 10.1016/j.ophtha.2009.10.017. PMID: 20163864. PMCID: PMC2864326. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951623319&origin=inward.

49. Woodward JA, Haggerty CJ, Stinnett SS, Williams ZY. 2010; Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol. 9:96–102. DOI: 10.1111/j.1473-2165.2010.00487.x. PMID: 20618554. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77954445858&origin=inward.

50. Yoelin SG, Fagien S, Cox SE, Davis PG, Campo A, Caulkins CA, Gallagher CJ. 2014; A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Dermatol Surg. 40:1118–1124. DOI: 10.1097/01.DSS.0000452658.83001.d9. PMID: 25229783. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84909583005&origin=inward.

51. Kwon O, Kim JY, Paik SH, Jeon HC, Jung YJ, Lee Y, Baek JH, Chun JH, Lee WS, Lee JY, Rogers JD, Halstead M, Eun HC. 2014; Long-term utility and durability of the therapeutic effects of bimatoprost 0.03% for eyelash augmentation in healthy Asian subjects. Dermatology. 229:222–229. DOI: 10.1159/000363379. PMID: 25228046. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84913615048&origin=inward.

52. Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. 2012; Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol. 39:865–866. DOI: 10.1111/j.1346-8138.2012.01579.x. PMID: 22594928. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84867098787&origin=inward.

53. Glaser DA, Hossain P, Perkins W, Griffiths T, Ahluwalia G, Weng E, Beddingfield FC. 2015; Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol. 172:1384–1394. DOI: 10.1111/bjd.13443. PMID: 25296533. PMCID: PMC4832276. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84929129951&origin=inward.

54. Vila TO, Camacho Martinez FM. 2010; Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichology. 2:86–88. DOI: 10.4103/0974-7753.77511. PMID: 21712909. PMCID: PMC3107964. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861320499&origin=inward.

55. Zaheri S, Hughes B. 2010; Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol. 35:e161–e162. DOI: 10.1111/j.1365-2230.2009.03755.x. PMID: 19925481. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951247075&origin=inward.

56. Law SK. 2010; Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 4:349–358. DOI: 10.2147/OPTH.S6480. PMID: 20463804. PMCID: PMC2861943. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77953374959&origin=inward.

57. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. 2009; Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 60:705–706. DOI: 10.1016/j.jaad.2008.08.029. PMID: 19293023. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=61949178512&origin=inward.

58. Borchert M, Bruce S, Wirta D, Yoelin SG, Lee S, Mao C, VanDenburgh A. 2016; An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin Ophthalmol. 10:419–429. DOI: 10.2147/OPTH.S89561. PMID: 27022239. PMCID: PMC4792214. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84961148688&origin=inward.

59. Subedi L, Pandey P, Shim JH, Kim KT, Cho SS, Koo KT, Kim BJ, Park JW. 2022; Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia. Drug Deliv. 29:328–341. DOI: 10.1080/10717544.2022.2027046. PMID: 35040730. PMCID: PMC8774136. PMID: 4ee435de62364ca4a794eb4b7e77d295. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123354630&origin=inward.

60. Hwang JH, Chu H, Ahn Y, Kim J, Kim DY. 2019; HMGB1 promotes hair growth via the modulation of prostaglandin metabolism. Sci Rep. 9:6660. DOI: 10.1038/s41598-019-43242-2. PMID: 31040377. PMCID: PMC6491442. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064925362&origin=inward.

61. Villarreal-Villarreal CD, Sinclair RD, Martínez-Jacobo L, Garza-Rodríguez V, Rodríguez-León SA, Lamadrid-Zertuche AC, Rodríguez-Gutierrez R, Ortiz-Lopez R, Rojas-Martinez A, Ocampo-Candiani J. 2019; Prostaglandins in androgenetic alopecia in 12 men and four female. J Eur Acad Dermatol Venereol. 33:e214–e215. DOI: 10.1111/jdv.15479. PMID: 30730082. PMID: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85062335498&origin=inward.